Syndicated Research Report Healthcare IT & Digital Health

AI-Enabled Imaging Modalities Market

Size, Share & Industry Analysis, By Modality (MRI, CT, Ultrasound, X-ray and Mammography, Other Imaging), By Application (Oncology, Neurology, Cardiology, Musculoskeletal, Obstetrics and Other), By End User (Hospitals, Diagnostic Imaging Centers, Specialty Clinics, Other), By Deployment (Fixed Imaging Systems, Portable and Point-of-Care Systems), and Global Forecast, 2026-2034

Report ID 24LS-12822
Pages 125
Last Updated
Author 24LifeSciences Research Team
Industry Healthcare IT & Digital Health
Starting from $995 USD

Market Overview

2026 Market SizeUSD 7.6 BnBase year
2027 EstimateUSD 8.4 BnEstimated year
2036 ForecastUSD 21.4 BnForecast value
CAGR10.9%2027–2036
Largest RegionNorth America2026

AI-Enabled Imaging Modalities Market Overview

The global AI-enabled imaging modalities market is valued at USD 7.6 billion in 2026, estimated at USD 8.4 billion in 2027, and projected to reach USD 21.4 billion by 2036, expanding at a 10.9% CAGR during 2027–2036.

2025FDA clearance year for Philips SmartSpeed PrecisePhilips
2025Launch year of GE Invenia ABUS PremiumGE HealthCare
2026India deployment of Swoop portable MRIHyperfine
2025FDA draft AI device lifecycle guidanceFDA

The AI-enabled imaging modalities market includes CT, MRI, ultrasound, X-ray and mammography systems with integrated artificial intelligence that supports acquisition, reconstruction, quality control or diagnostic workflow. The revenue boundary covers the AI-enabled equipment and its associated modality-specific embedded software rather than every stand-alone radiology algorithm. This distinction limits double counting when a hospital buys an AI-enabled scanner and separately licenses image-analysis software.

Manufacturers are deploying AI to shorten scan preparation, improve reconstruction and support image interpretation. Philips received FDA clearance for SmartSpeed Precise in July 2025 and described acceleration and sharpness gains under its stated testing conditions. GE HealthCare introduced AI-enabled automated breast ultrasound in March 2025. Such deployments show why imaging providers increasingly evaluate AI at the time of hardware procurement, rather than only as an independent informatics purchase.

The market estimate normalizes the publisher’s 2025 revenue reference of USD 6,831 million and 2032 projection of USD 14,119 million to the current 2026, 2027 and 2036 framework. The normalized annual growth rate is 10.93%, rounded to 10.9% for publication. These figures describe an estimated global revenue opportunity and should not be interpreted as audited vendor-reported sales of AI-specific imaging products.

The FDA maintains a public list of authorized AI-enabled devices and issued draft lifecycle guidance in January 2025 addressing transparency, bias and changes over time. WHO guidance emphasizes governance and human oversight for health AI. Buyers therefore assess workflow compatibility, radiologist trust, cybersecurity and post-market monitoring alongside imaging speed or diagnostic performance.

Source: FDA AI-enabled medical device list; Philips SmartSpeed Precise; GE Invenia ABUS Premium; FDA lifecycle guidance.

Key Takeaways: AI-Enabled Imaging Modalities Market

  • Base-year market size: Global revenue is estimated at USD 7.6 billion in 2026.
  • Forecast and CAGR: Revenue is projected at USD 21.4 billion in 2036, with a 10.9% CAGR from 2027.
  • Leading modality: MRI systems represented an estimated ~32% of 2026 revenue in the publisher-normalized model.
  • Leading application: Oncology imaging represented an estimated ~29% of 2026 revenue across applications.
  • Largest region: North America represented an estimated ~39% of 2026 revenue.
  • Growth drivers: AI-assisted reconstruction, capacity constraints and demand for faster examinations support procurement.
  • Competitive landscape: Philips, Siemens Healthineers, GE HealthCare, Fujifilm and Hologic compete with specialist portable imaging suppliers.
  • Report coverage: Four segmentation axes, five geographic regions and the 2027–2036 outlook are assessed.

Report Scope & Market Segmentation

This study measures manufacturer revenue attributable to AI-enabled diagnostic imaging equipment and associated integrated modality software, distinguishing scanners from standalone diagnostic algorithms.

Report AttributeCoverage
Base Year2026
Estimated Year2027
Forecast Period2027–2036
Market MeasurementRevenue, USD million/billion
By ModalityMRI; CT; Ultrasound; X-ray and Mammography; Other Imaging
By ApplicationOncology; Neurology; Cardiology; Musculoskeletal; Obstetrics and Other
By End UserHospitals; Diagnostic Imaging Centers; Specialty Clinics; Other
By DeploymentFixed Imaging Systems; Portable and Point-of-Care Systems
By RegionNorth America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Selected CountriesUnited States; Canada; Germany; United Kingdom; China; Japan; India; Brazil; Saudi Arabia
Key Market PlayersPhilips; Siemens Healthineers; GE HealthCare; Canon Medical Systems; Agfa HealthCare; Hologic; Fujifilm; Konica Minolta; United Imaging; Exo Imaging; Nanox; Butterfly Network; Hyperfine; Aidoc; MRIguidance

Market Definition & Revenue Boundaries

The counted market comprises new AI-enabled diagnostic scanners and imaging platforms plus embedded acquisition, reconstruction, positioning and workflow software supplied as part of those modalities. Standalone enterprise PACS, unrelated clinical decision software, general-purpose computing and unapproved investigational concepts are excluded from counted commercial revenue.

A single scanner sale is assigned once to its principal modality, even when multiple AI functions are bundled. Applications reflect the primary clinical use; end users reflect the purchasing facility; and deployment distinguishes fixed installations from portable or bedside devices. Each segmentation axis independently totals the same global revenue base.

AI-Enabled Imaging Modalities Market Dynamics

Drivers Impact Analysis*

Market DriversImpact RankCAGR Contribution (%)2027–20292030–20322033–2036
AI reconstruction and faster acquisition workflowsHigh+4.20%HighHighMedium
Clinical demand for diagnostic imaging capacityHigh+3.50%HighHighHigh
Integrated AI product upgrades and replacement cyclesMedium+2.80%MediumHighHigh
Portable imaging and emerging-market adoptionMedium+2.10%MediumMediumHigh
Others (interoperability and service improvements)Low+1.40%LowMediumMedium

Restraints Impact Analysis*

Market RestraintsImpact RankCAGR Contribution (%)2027–20292030–20322033–2036
Hospital capital expenditure limitationsHigh-1.40%HighMediumMedium
Regulatory validation and local performance requirementsMedium-0.90%HighMediumMedium
Cybersecurity and integration costsMedium-0.50%MediumMediumMedium
Others (staffing and reimbursement constraints)Low-0.30%MediumLowLow

*CAGR contribution shows the percentage points each factor adds to or removes from the 10.9% CAGR for 2027–2036; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

Radiology backlogs create a case for AI-enabled throughput

Radiology departments are balancing growing scan volumes against constrained staff capacity and long appointment queues. Reconstruction algorithms can accelerate MRI acquisitions and reduce the burden of repeat scans, while AI-assisted positioning and protocol selection help standardize work between operators. Philips described its SmartSpeed Precise dual-AI platform in July 2025, illustrating the commercial focus on scanner productivity. The revenue opportunity expands when hospitals can demonstrate measurable gains in throughput without compromising image quality, safety or physician oversight.

Integrated AI makes new imaging platforms more attractive

Imaging vendors increasingly integrate algorithms with scanners instead of treating AI as a disconnected software purchase. GE HealthCare introduced Invenia ABUS Premium in March 2025 with AI-assisted acquisition and reading functionality, while Philips has extended AI reconstruction across its MRI portfolio. Adoption nevertheless depends on modality-specific clinical validation, compatibility with existing archives and information systems, and the willingness of purchasers to fund higher upfront equipment expenditure. Philips and GE HealthCare also offer established clinical equipment service networks.

Regulatory requirements shape purchasing and product development

The FDA maintains a list of authorized AI-enabled medical devices and published draft lifecycle guidance in January 2025 addressing transparency, bias and updates. Imaging manufacturers must document intended use and performance while health systems assess algorithm drift and local patient populations. This creates engineering and validation costs that can delay commercialization, particularly for smaller vendors. It also favors suppliers that combine clinical evidence, quality management and established service networks with equipment procurement and long-term maintenance contracts, supported by application-specific service teams.

Capital budgets and integration complexity restrain deployment

Large MRI and CT installations require capital investment, room preparation, staff training and integration with PACS and electronic records. AI features may improve productivity, but savings depend on scheduling, staffing and case mix rather than scanner specifications alone. Hospitals therefore compare lifecycle costs, reimbursement, cybersecurity and upgrade options before procurement. Standalone AI tools can also compete for the same digital-imaging budgets, creating a risk of double-counting demand unless the equipment and software revenue boundaries remain clearly separated.

Portable imaging extends the addressable care setting

Hyperfine announced FDA clearance for its next-generation Swoop portable MRI in June 2025, followed by a reported clinical deployment at AIIMS New Delhi in April 2026. Butterfly Network has also developed AI-supported point-of-care ultrasound workflows. These examples demonstrate a shift toward imaging closer to the patient, including intensive care and resource-constrained facilities. Portable devices are unlikely to replace high-field scanners for all indications, but they can expand access to focused examinations where transport or infrastructure presents a barrier.

Sources: FDA; Philips; GE HealthCare; Hyperfine; Butterfly Network.

AI-Enabled Imaging Modalities Market Segmentation by Modality

Report Segmentation
By Modality

AI-enabled imaging equipment is segmented into MRI, CT, Ultrasound, X-ray and Mammography, and Other Imaging. Each system is assigned once to its primary imaging technology.

Leading Modality

MRI

MRI represented an estimated ~32% of 2026 revenue. Philips SmartSpeed Precise and Hyperfine Optive AI illustrate how reconstruction algorithms can be embedded in both fixed and portable MR systems. Hospitals evaluate scanner productivity, clinical quality and equipment lifecycle costs when making purchasing decisions.

High-Volume Platform

CT

CT vendors increasingly use intelligent reconstruction and workflow support to manage complex scanning demand. Siemens Healthineers documents AI-Rad Companion CT solutions, although separate post-processing licenses are excluded from this equipment-focused market boundary.

Point-of-Care Opportunity

Ultrasound

AI-assisted ultrasound expands opportunities for portable imaging and acquisition support. GE HealthCare introduced Invenia ABUS Premium for breast imaging and Butterfly Network has developed AI-enabled point-of-care workflow tools.

The modality mix is expected to diversify as embedded AI becomes standard across imaging hardware, with MRI retaining a substantial share of premium system revenue. Equipment makers differentiate their portfolios through integrated acquisition controls, deep learning reconstruction and applications tied to specific scanner models. The FDA device database provides product-level authorization information, but its list should not be interpreted as a revenue ranking. Imaging buyers also compare installation costs, uptime, service availability and training requirements. Across modalities, software updates can extend equipment usefulness while major hardware replacement continues to depend on clinical capacity and capital planning. Portable ultrasound and MRI serve narrower use cases and are counted under their respective imaging modality rather than as a separate overlapping category.

AI-Enabled Imaging Modalities Market Segmentation by Application

Report Segmentation
By Application

Applications include Oncology, Neurology, Cardiology, Musculoskeletal, and Obstetrics and Other. Revenue is allocated to the principal clinical indication of the installed equipment.

Leading Application

Oncology

Oncology imaging represented an estimated ~29% of 2026 revenue. Breast screening, lesion detection and treatment planning require dependable image acquisition and interpretation support. GE HealthCare and Hologic offer AI-enabled breast imaging capabilities that illustrate the category.

Neurological Imaging

Neurology

Brain imaging benefits from reconstruction, motion reduction and bedside access. Hyperfine portable MRI demonstrates how AI-enhanced image formation can support neurological examinations in settings without conventional MRI access.

Cardiovascular Imaging

Cardiology

AI-assisted cardiac imaging supports workflow standardization and reconstruction. Philips introduced AI-enabled cardiac MR innovations in November 2025, indicating growing supplier attention to complex cardiac acquisition.

Clinical adoption varies by specialty and should be assessed against validated indications rather than assuming one algorithm is suitable for every patient group. Breast imaging illustrates the intersection of oncology and modality-specific AI: GE HealthCare introduced AI-assisted automated breast ultrasound in 2025, and Hologic markets mammography decision support. Neurology includes portable brain imaging and reconstruction technologies, while cardiology benefits from AI-assisted scan planning. A hospital purchasing a multi-purpose scanner may use it for several specialties, so allocation by primary clinical purpose is an estimation method, not a count of distinct machines for each disease. Adoption depends on specialist workflow and evidence of practical diagnostic value.

AI-Enabled Imaging Modalities Market Segmentation by End User

Report Segmentation
By End User

The end-user split covers Hospitals, Diagnostic Imaging Centers, Specialty Clinics and Other purchasers, based on the organization acquiring the imaging system.

Leading Buyer

Hospitals

Hospitals are the largest purchasers of advanced MRI, CT and integrated imaging systems. They assess equipment replacement cycles, throughput gains, service contracts and interoperability before approving AI-enabled capital spending.

Outpatient Expansion

Diagnostic Imaging Centers

Imaging centers emphasize scanner utilization and examination turnaround. AI reconstruction and standardized acquisition can be attractive when performance gains translate into additional appointment capacity.

Specialty Adoption

Specialty Clinics

Breast clinics, neurology practices and point-of-care facilities are potential buyers of modality-specific systems. Portable MRI and ultrasound can broaden access without replacing comprehensive hospital imaging services.

Procurement decisions depend on reimbursement, clinical staffing and equipment financing, making growth uneven across facility types. Hospital purchasing decisions often involve radiology leadership, biomedical engineering, finance and information technology. Diagnostic imaging centers may prioritize predictable scanning schedules, whereas specialty practices seek focused applications with manageable staffing requirements. Service coverage is especially important for capital-intensive systems, because downtime can eliminate expected throughput benefits. The model counts manufacturer sales to the purchasing institution rather than adding downstream patient fees or reimbursement receipts. This approach separates equipment revenue from provider service revenue and makes comparisons across facility types more consistent over the forecast period. Equipment service terms are considered alongside hardware price in hospital purchasing.

AI-Enabled Imaging Modalities Market Segmentation by Deployment

Report Segmentation
By Deployment

Deployment distinguishes fixed installations from portable and point-of-care systems.

Installed Revenue Base

Fixed Imaging Systems

Fixed scanners dominate high-value MRI and CT procurement because they serve broad clinical indications and support complex imaging protocols. AI features are increasingly integrated into the equipment and software upgrade cycle.

Access Expansion

Portable and Point-of-Care Systems

Portable systems are gaining attention where moving patients to a scanner is difficult. Hyperfine reported bedside MRI adoption in India in April 2026, while Butterfly Network markets handheld ultrasound and AI-assisted workflow capabilities.

Portable deployment is expected to grow from a smaller revenue base, while fixed systems remain central to high-acuity diagnostic imaging. Fixed installations typically involve room preparation, power and cooling requirements, dedicated technologists and long service agreements. Portable devices may reduce the need to transport critically ill patients, but their imaging resolution and intended clinical indications differ from full-size scanners. Hyperfine reported AIIMS New Delhi deployment of portable brain MRI in April 2026; Butterfly Network provides handheld ultrasound products with AI-enabled workflow functions. Purchasing decisions depend on portability, clinical performance, staff competence, maintenance and the extent of approved use. Revenue is assigned to one deployment category per equipment sale. Hyperfine announced FDA clearance for its redesigned portable Swoop MRI in June 2025. Hyperfine describes its Swoop product for brain imaging of patients under defined clinical conditions. Fixed CT and MRI equipment serves different indications.

AI-Enabled Imaging Modalities Market Regional Analysis

Regional demand reflects imaging infrastructure, reimbursement, capital investment, regulatory authorization and adoption of integrated artificial intelligence. North America is modeled as the largest revenue region in 2026, while Asia-Pacific offers significant long-term capacity expansion.

North America

Largest market - ~39% of global revenue in 2026

North America represented an estimated ~39% of 2026 revenue. The region combines a substantial installed base of MRI, CT and mammography equipment with established device regulatory pathways and strong manufacturer service networks. The FDA maintains an AI-enabled device list and published draft lifecycle guidance in January 2025. Hospitals are testing integrated reconstruction, screening support and scanner workflow features to manage examination demand. Large providers may adopt advanced equipment first, while community facilities evaluate upgrades against capital constraints and staffing availability. North American growth is therefore shaped by replacement cycles, clinical evidence and the ability to demonstrate measurable throughput improvements rather than AI branding alone. Imaging vendors with established U.S. distribution and service relationships can support software upgrades on installed systems. Procurement teams still need to distinguish integrated modality software from separately licensed image-analysis tools.

Priority country signals

United States

Selected market signal

The United States is the principal regional purchasing market for advanced scanners and imaging software. The FDA has authorized numerous AI-enabled devices and issued draft lifecycle guidance in January 2025. Philips announced FDA clearance for SmartSpeed Precise in July 2025, and Hyperfine announced its next-generation portable MRI clearance in June 2025. Authorization of a device does not establish that every imaging center has adopted it; local procurement and clinical evaluation remain necessary.

Source: FDA.

Canada

Selected market signal

Canadian imaging providers face similar pressures around examination capacity and aging infrastructure, but procurement depends on provincial funding and local evaluation. AI-enabled reconstruction may be attractive where throughput can be improved without expanding scanner rooms. Local assessment of imaging workflow benefits is important because scanner replacement is funded through multiple provincial and institutional channels.

Source: WHO.

Europe

Established market - Clinical governance and procurement

Europe has established diagnostic imaging infrastructure and an active base of imaging equipment manufacturers and hospital purchasers. Philips announced its SmartSpeed Precise technology in February 2025 and subsequently received FDA clearance in July, illustrating a multinational development pathway for integrated MRI AI. European purchasing decisions vary by country, health technology assessment, reimbursement and public procurement processes. Hospitals prioritize image quality, operational efficiency and the cost of scanner replacement, while privacy and clinical governance influence software deployment. The market includes premium fixed systems and an emerging role for specialized portable devices. Vendor competition is based on modality breadth, service support and compatibility with existing clinical imaging systems. Supplier documentation and national regulatory requirements are relevant to adoption, while public hospital capital cycles can differ substantially between countries. Regional revenue forecasts therefore reflect a mixture of scanner replacement and new installations.

Priority country signals

Germany

Selected market signal

Germany hosts Siemens Healthineers and a broad hospital imaging infrastructure. The company publishes AI-Rad Companion technical documentation covering CT and X-ray use cases. Providers weigh performance, reimbursement and long-term support when introducing AI-enabled imaging functions. Regional procurement is influenced by established hospital scanner fleets and the ability to integrate software with existing clinical records.

Source: Siemens Healthineers.

United Kingdom

Selected market signal

The United Kingdom combines centralized health-system procurement with demand to improve radiology capacity. AI reconstruction and workflow automation may reduce examination bottlenecks where supported by clinical evaluation. Providers must distinguish approved clinical functionality from research-stage concepts and verify interoperability with existing imaging infrastructure. Public procurement requires evidence that the technology addresses service needs and can be supported within existing staffing and information systems.

Source: WHO.

Asia-Pacific

Expansion opportunity - Infrastructure and portable adoption

Asia-Pacific includes mature imaging markets such as Japan and Australia alongside expanding healthcare infrastructure in China and India. Fujifilm introduced SYNAPSE SAI viewer version 2.7 in Japan in July 2025, extending support for MRI interpretation and CT lymph-node labeling. Hyperfine reported that AIIMS New Delhi initiated clinical use of its portable MRI system in April 2026, indicating potential for specialized bedside applications. Regional growth depends on capital budgets, domestic equipment supply, hospital modernization and access to trained imaging staff. Portable and point-of-care systems can complement conventional scanners in locations where transport and infrastructure are challenging, while high-end fixed systems remain important for complex diagnosis. Equipment service capacity, operator training and local authorization requirements vary considerably across the region. Market growth should be linked to verified clinical deployments and procurement rather than simply to general interest in AI.

Priority country signals

Japan

Selected market signal

Fujifilm expanded its SYNAPSE SAI viewer in July 2025 with MRI and CT support capabilities. Japanese imaging providers can combine established scanner fleets with AI-enabled workflow improvements, subject to local regulatory authorization and institutional evaluation. Its established medical technology industry and high imaging capacity make software integration and equipment upgrades relevant purchasing considerations.

Source: Fujifilm.

India

Selected market signal

Hyperfine reported the clinical introduction of its Swoop portable MRI at AIIMS New Delhi in April 2026. This is an example of bedside imaging adoption rather than evidence that portable systems can replace conventional diagnostic MRI for every indication. The reported deployment illustrates a specialized neurological use case; wider adoption depends on equipment affordability, clinical training and maintenance.

Source: Hyperfine.

Latin America

Developing market - Access and financing

Latin American imaging adoption is shaped by public and private capital spending, unequal distribution of advanced equipment and the availability of trained radiology staff. Larger urban hospitals are likely to lead purchases of AI-enabled MRI and CT platforms, while smaller facilities may prioritize equipment affordability, maintenance and connectivity. AI reconstruction and acquisition assistance can be useful when they improve productivity on existing systems, but actual gains depend on local clinical workflows. Regional growth is expected to be gradual and concentrated in healthcare networks able to justify premium scanner investment. The market model treats this region separately from North America to preserve consistent geographic totals. Large urban hospital systems may be the earliest adopters of premium equipment, while smaller facilities often depend on leasing, service coverage and public budgets.

Priority country signals

Brazil

Selected market signal

Brazil is a major Latin American healthcare market with public and private diagnostic imaging demand. Procurement of AI-enabled systems depends on equipment financing, regulatory authorization and the availability of qualified staff. Urban diagnostic networks may evaluate reconstruction features to increase utilization without expanding facility footprints. Different funding arrangements between private diagnostic networks and public hospitals can produce uneven equipment replacement cycles.

Source: FDA.

Mexico

Selected market signal

Mexico presents opportunities for equipment modernization in larger hospital and imaging networks. The economic case for integrated AI must account for service contracts, maintenance, connectivity and reimbursement. AI functionality does not eliminate the need for trained radiologists and validated examination protocols. Facilities must also consider equipment downtime, local service availability and the ability to maintain approved imaging workflows.

Source: WHO.

Middle East & Africa

Emerging market - Specialty imaging investment

The Middle East and Africa region has heterogeneous imaging capacity, ranging from well-funded tertiary hospitals to facilities with limited access to MRI and CT. Premium hospital projects may incorporate AI-enabled scanners as part of new equipment installations, while portable ultrasound and specialized bedside imaging offer different access pathways. Adoption depends on training, service infrastructure, regulatory approvals and sustainable financing. WHO guidance on governance highlights the importance of reliable clinical oversight when advanced AI is introduced. The region is expected to remain a smaller share of global revenue, although selected national healthcare modernization programs may support faster growth from a low base. Forecasts should not equate announced digital-health ambitions with confirmed scanner sales. Demand for high-end equipment is likely to remain concentrated in major referral centers, with portable ultrasound offering a different, lower-infrastructure access route.

Priority country signals

Saudi Arabia

Selected market signal

Saudi healthcare investment can support advanced diagnostic imaging in tertiary facilities, but purchasing decisions remain tied to clinical requirements, procurement procedures and long-term servicing. Integrated AI is most valuable when accompanied by workflow validation and staff training. Large referral hospitals can support advanced installations, but actual adoption is tied to tender outcomes and clinical capacity needs.

Source: WHO.

South Africa

Selected market signal

South Africa has a mix of private imaging networks and constrained public-sector capacity. AI-assisted acquisition may offer efficiency gains, but financing, reliable equipment maintenance and access to specialist readers are important limitations. Urban private facilities may be better positioned to fund new equipment, while public hospitals face different capital and staffing constraints.

Source: WHO.

Competitive Landscape

The competitive landscape combines multinational scanner manufacturers with specialized developers of portable imaging and modality-specific AI. Equipment integration, clinical evidence, installed-base service and regulatory readiness determine commercial positioning.

Integrated Imaging Leaders

Philips, Siemens Healthineers and GE HealthCare

Philips has introduced SmartSpeed Precise for MRI, Siemens Healthineers documents AI-Rad Companion solutions, and GE HealthCare launched Invenia ABUS Premium. These vendors combine equipment portfolios with integrated software and service relationships.

Breast Imaging Specialists

Hologic and Fujifilm

Hologic markets Genius AI Detection for mammography and Fujifilm has expanded AI-assisted image viewing. The suppliers emphasize workflow support and clinically relevant imaging features, although viewer-only revenue is excluded from equipment totals.

Portable Imaging Innovators

Hyperfine and Butterfly Network

Hyperfine has commercialized an AI-powered portable brain MRI platform, while Butterfly Network develops handheld ultrasound and enterprise workflow tools. Their offerings target clinical settings where conventional imaging access is limited.

Broader Equipment Ecosystem

Canon Medical, United Imaging and Konica Minolta

Established imaging manufacturers compete across modality portfolios and geographic distribution networks. The report tracks their positioning while distinguishing verified AI-enabled equipment functionality from broader corporate product claims.

Competitive differentiation increasingly rests on clinical performance, reliable image reconstruction and compatibility with existing equipment. Hospitals evaluate whether algorithms improve workflow without creating new validation or training burdens. Product availability varies by country and regulatory status, so an announced feature should not automatically be treated as a globally commercialized product. Philips announced SmartSpeed Precise clearance in July 2025, while GE HealthCare introduced AI-assisted breast ultrasound in March 2025. These dated releases provide examples of competition through modality-specific functionality rather than a single general AI platform.

Partnerships between imaging manufacturers, software developers and computing suppliers can accelerate AI integration. GE HealthCare described NVIDIA-enabled imaging advances in December 2025, while Philips discussed collaboration with NVIDIA in May 2025. Such announcements demonstrate technology direction but do not alone establish market share or incremental device revenue. Hyperfine and Butterfly Network focus on narrower deployment environments than conventional fixed scanner manufacturers. Hologic provides breast imaging solutions, while Fujifilm expanded its image viewing capabilities in 2025. Product comparisons therefore require attention to hardware integration, approved indications and regional availability.

Key Companies Profiled

  • Philips
  • Siemens Healthineers
  • GE HealthCare
  • Canon Medical Systems
  • Agfa HealthCare
  • Hologic
  • Fujifilm
  • Konica Minolta
  • United Imaging
  • Exo Imaging
  • Nanox
  • Butterfly Network
  • Hyperfine
  • Aidoc
  • MRIguidance

Recent Developments in the AI-Enabled Imaging Modalities Market

April 2026: Hyperfine reported that AIIMS New Delhi initiated clinical use of its Swoop portable MRI system, an example of bedside brain imaging deployment in India. The announcement concerned a specific institutional deployment and should not be extrapolated to national installed-base totals. Deployment of portable MRI in a tertiary care environment provides a concrete example of how bedside imaging can complement conventional radiology services. Source

December 2025: GE HealthCare introduced imaging innovations using NVIDIA technology, including new platforms shown at RSNA 2025. The company highlighted accelerated imaging and workflow capabilities across several modalities, with commercial status differing by product and jurisdiction. The announced innovations covered multiple imaging platforms, emphasizing that AI functionality is becoming part of broader equipment development programs. Source

November 2025: Butterfly Network launched Compass AI, a platform designed to support documentation, governance and operations for point-of-care ultrasound programs. The product is relevant to imaging workflow integration, although software-only platform revenue is excluded from scanner hardware totals. The product addresses ultrasound program operations and documentation, a different commercial category from the sale of physical ultrasound equipment. Source

July 2025: Philips announced FDA 510(k) clearance of SmartSpeed Precise dual-AI MRI reconstruction software. The company described faster scanning and improved image sharpness under stated conditions, supporting integration of AI functionality into its installed MRI portfolio. The clearance applies to defined MRI software functionality and does not mean every scanner or protocol achieves the same performance improvements. Source

June 2025: Hyperfine announced FDA clearance of a redesigned Swoop portable MRI system powered by Optive AI software. The development combines hardware redesign with AI-assisted reconstruction for bedside brain imaging in supported clinical use cases. The system is intended for brain imaging under specified conditions and should be compared with conventional scanners only within relevant clinical indications. Source

March 2025: GE HealthCare launched Invenia ABUS Premium, a breast ultrasound system featuring AI-supported acquisition and reading workflows. The announcement demonstrates continued investment in imaging-specific AI functionality rather than general-purpose clinical AI software. The platform targets supplemental breast screening, with AI functions integrated into acquisition and interpretation support workflows. Source

Market Outlook, 2027–2036

The AI-enabled imaging modalities market is projected to expand from USD 8.4 billion in 2027 to USD 21.4 billion in 2036, representing a 10.9% CAGR during 2027–2036. Growth is expected to reflect embedded AI adoption across scanner replacement and new installations.

Forecast Variable2027 PositionExpected Effect Through 2036
MRI reconstructionEstablished vendor integrationFurther integration into scanner platforms
Breast imaging AICommercial screening applicationsBroader acquisition and interpretation support
Portable imagingEarly clinical deploymentsAdditional point-of-care use cases
Regulatory oversightFDA lifecycle expectationsContinued validation and monitoring
Hospital capital budgetsVariable purchasing capacityReplacement-cycle-driven deployment

The outlook assumes AI-assisted acquisition and reconstruction become more common features of diagnostic imaging systems. The publisher-normalized model places 2026 revenue at USD 7.6 billion and 2027 revenue at USD 8.4 billion, with a forecast of USD 21.4 billion in 2036. These are market estimates rather than audited AI-specific vendor sales. Future demand will depend on scanner replacement, software upgrade policies, and the ability of providers to document clinical and operational benefits.

MRI is expected to remain an important contributor because deep learning reconstruction can influence both scanner throughput and image quality. CT, mammography and ultrasound systems will also incorporate modality-specific intelligence. However, differences in indications, imaging physics and regulatory authorization mean that one AI feature cannot be generalized across all scanner types. Manufacturers with established service networks may have an advantage in delivering validated upgrades to large installed fleets.

Portable MRI and ultrasound provide an additional growth pathway, particularly where bedside imaging or limited infrastructure makes conventional scanner access difficult. Hyperfine reported a new portable MRI clearance in 2025 and a deployment in India in 2026. Butterfly Network has advanced AI-enabled point-of-care ultrasound workflows. These products may expand access but should not be treated as interchangeable with premium fixed MRI and CT platforms.

The FDA device list and draft lifecycle guidance indicate that authorization, monitoring and transparency are important to commercial deployment. WHO guidance also stresses governance of health AI. Adoption may be slower where reimbursement, procurement funding or cybersecurity readiness is limited. Conversely, evidence of improved workflow, supported by clinician training and vendor service, could accelerate investment.

North America leads modeled 2026 revenue, while European buyers emphasize clinical governance and Asia-Pacific offers infrastructure expansion opportunities. The forecast assumes the market retains a clear revenue boundary around imaging equipment and embedded modality software, excluding unrelated stand-alone AI applications. This prevents inflation from counting the same clinical workflow twice.

Report Coverage

The study covers AI-enabled imaging systems, their integrated modality software, major clinical uses and procurement environments.

Market Sizing & Forecasting2026 base, 2027 estimate, 2036 projection and 2027–2036 CAGR.
Modality SegmentationMRI, CT, ultrasound, X-ray and mammography, and other imaging.
Application SegmentationOncology, neurology, cardiology, musculoskeletal and other applications.
End User & DeploymentHospitals, imaging centers, specialty clinics and fixed versus portable systems.
Regional AnalysisFive regions and priority country procurement signals.
Competitive and Regulatory LandscapeManufacturer products, FDA authorization, integration and governance.

Frequently Asked Questions

How large is the AI-enabled imaging modalities market?

The global market is estimated at USD 7.6 billion in 2026 and USD 8.4 billion in 2027, with a projection of USD 21.4 billion by 2036. The estimate includes imaging systems with integrated AI functions and excludes unrelated stand-alone enterprise software.

What is the forecast CAGR for AI-enabled imaging modalities?

The publisher-normalized forecast implies a 10.9% compound annual growth rate over 2027–2036. The projection is calculated across nine years using the 2027 estimate and 2036 forecast. Actual growth depends on equipment procurement, clinical adoption and product authorization.

Which imaging modality leads the market?

MRI is modeled as the leading modality, representing an estimated ~32% of 2026 revenue, supported by integrated reconstruction and workflow technologies. Other modalities include CT, ultrasound and mammography. Shares are modeled allocations of the global equipment revenue base, not manufacturer-reported category totals.

Which region has the largest share?

North America represented an estimated ~39% of 2026 revenue in the market model, supported by a substantial imaging equipment installed base. The regional estimate reflects established imaging infrastructure and supplier distribution. Growth in other regions will depend on capital investment, regulatory authorization and service capacity.

What are examples of AI-enabled MRI?

Philips SmartSpeed Precise and Hyperfine Swoop with Optive AI are examples of AI-enabled MRI capabilities in fixed and portable systems. These products use AI for reconstruction or image enhancement in their respective intended settings. Philips announced SmartSpeed Precise FDA clearance in July 2025.

How is AI used in breast imaging?

GE HealthCare Invenia ABUS Premium and Hologic Genius AI are relevant examples. The relevant functions differ between automated breast ultrasound and mammography. Clinical interpretation remains the responsibility of qualified professionals using approved systems. The FDA maintains a public AI-enabled medical device list with authorization details.

Are AI-enabled medical imaging devices regulated?

Yes. The FDA maintains a public list of authorized AI-enabled medical devices. Health systems must also assess local performance, governance and appropriate post-deployment oversight. The FDA issued draft AI device lifecycle guidance in January 2025. Hyperfine announced its next-generation Swoop MRI clearance in June 2025.

Does AI replace radiologists?

AI functions support acquisition, reconstruction and interpretation workflows, but clinical oversight and validated intended use remain essential. Algorithms may reduce repetitive tasks and improve image quality, but their performance is dependent on the use case, input data and deployment environment.

Which companies compete in AI-enabled imaging?

Major participants include Philips, GE HealthCare, Siemens Healthineers, Fujifilm, Hologic, Hyperfine and Butterfly Network. The competitive field also includes broader scanner manufacturers and specialized software developers. The equipment market excludes stand-alone software that is not bundled with an imaging modality.

What limits adoption of AI-enabled imaging equipment?

Capital budgets, regulatory validation, cybersecurity, workflow integration, clinical evidence and staff training can slow deployment. A purchaser must assess whether productivity improvements justify capital costs. Software interoperability and vendor support can be as important as algorithm performance.

What is the role of portable AI imaging?

Portable MRI and ultrasound can extend access to bedside and point-of-care examinations, within their cleared clinical indications. These systems are useful in settings where patient transport or fixed imaging infrastructure is difficult. Butterfly Network launched Compass AI in November 2025.

What is the market outlook through 2036?

Revenue is projected at USD 21.4 billion by 2036 as integrated AI features spread across equipment replacement and new installations. The forecast assumes further integration of AI features into equipment platforms. Uncertainty remains around capital budgets, reimbursement and the pace of regulatory approvals.

Research Sources & Evidence Base

View research sources used for this overview
  1. FDA. AI-enabled medical device list, October 2026.
  2. FDA. AI device lifecycle draft guidance, January 2025.
  3. WHO. AI governance guidance, January 2024.
  4. Philips. SmartSpeed Precise FDA clearance, July 2025.
  5. Philips. BlueSeal Horizon MRI, November 2025.
  6. GE HealthCare. Invenia ABUS Premium, March 2025.
  7. GE HealthCare. Imaging with NVIDIA, December 2025.
  8. Siemens Healthineers. AI-Rad Companion DICOM conformance, April 2026.
  9. Fujifilm. SYNAPSE SAI viewer 2.7, July 2025.
  10. Hologic. Genius AI Detection PRO, May 2025.
  11. Hologic. Mammography AI research, September 2025.
  12. Butterfly Network. Compass AI platform, November 2025.
  13. Butterfly Network. AI gestational age tool, October 2025.
  14. Hyperfine. Swoop Optive AI clearance, June 2025.
  15. Hyperfine. AIIMS India portable MRI deployment, April 2026.
Trusted collaboration

Supporting teams across the life-sciences ecosystem

Focused market intelligence for commercial, strategy, product, and research teams across healthcare and life sciences.

Bain
Deloitte
PwC
Commercial Healthcare Partners
Client logo
Client logo
Life-sciences market focus Clear scope and sample review Confidential enquiry support

Display logos only where use is approved. A logo does not imply a public endorsement.

Client feedback

What teams value in their research experience

Feedback from research engagements, with client identities omitted where confidentiality applies.

Publish named testimonials only when the individual and organization have approved disclosure.

Research transparency

Built on a clearly defined research framework

Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.

Defined Market Scope

Coverage, segmentation, geography, and market boundaries are stated within the report.

Evidence-Led Overview

Readers can review the published sources and evidence referenced in this market overview.

Forecast Context

Base, estimated, and forecast years are shown to place the market outlook in context.

Current Publication Record

Each overview displays its report identifier and latest update date.

Report ID 24LS-12822
Base Year 2026
Forecast Period 2026–2036
Last Updated 16 Nov 2026
Inside the full report

What you can explore in this market report

A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.

01

Market Sizing & Forecasts

Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.

02

Segmentation Analysis

Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.

03

Regional Market View

Assess regional performance, selected country context, and factors shaping adoption across major markets.

04

Competition & Developments

Explore company profiles, market positioning, and selected developments relevant to the market landscape.

05

Market Dynamics & Trends

Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.

06

Research Methodology & Sources

Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.